Chongqing Huapont Shengchem Pharmaceutical Co., Ltd.

USP

20200618-211-J-455

1-naphthalenemethanamine,N-methyl-N-(3-phenyl-2-propenyl)-,hydrochloride(E)-(E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride

It is a synthetic alkylamine derivative with a broad antifungal range.

It inhibits squalene epoxidases, which are important enzymes for sterol biosynthesis, and exhibits antifungal action by depleting ergosterol in the fungal cell membrane.

65473-14-5

If you need more information, please contact us.

Divi’s Laboratories Limited.

USP

20130821-143-I-336-08(3)

(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid

(+)-(S)-6-Methoxy-α-methyl-2-naphthaleneacetic acid

(+)-(S)-Naproxen

(+)-2-(6-Methoxy-2-naphthyl)propionic acid

(+)-2-(Methoxy-2-naphthyl)-propionic acid

(+)-2-(Methoxy-2-naphthyl)-propionsäure

(+)-Naproxen

(S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid

(S)-(+)-Naproxen

(S)-2-(6-Methoxy-2-naphthyl)propanoic acid

(S)-2-(6-Methoxy-2-naphthyl)propionic acid

(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid

(S)-Naproxen

Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given it's overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.

22204-53-1

If you need more information, please contact us.

Zhejiang Charioteer Pharmaceutical Co., Ltd.

USP

20130121-143-I-209-04(6)

N/A

Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given it's overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers

26159-34-2

If you need more information, please contact us.